Global Health

Audio Journal of Global Health Issues: Drug Eluting Stents, PFO Closure: Indications Not Obvious

Mark Reisman

MARK REISMAN, Swedish Medical Center, Seattle

REFERENCE: ABSTRACT ACP Internal Medicine 2007, ERA 002
Drug eluting stents may not always be the automatic choice over the bare metal variety for patients requiring intervention, despite the important clinical advantages that have been emerging from their introduction recently. This is according to Mark Reisman who gave the Internal Medicine 2007 conference in San Diego his latest insights from the rapidly changing world of interventional cardiology. At this (recently renamed) annual meeting of the American College of Physicians he also discussed the difficult question of which patients are candidates for PFO closure, and what the clinical objectives of this might be: including the possible reduction of migraine headaches. After his session he talked with Peter Goodwin.

Similar Interviews

  • Drug-eluting Stents: No Benefit in Vein Grafts
  • Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis

  • Drug-eluting Stents: Cost-Benefit Targeting?
  • Matthias Pfisterer Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm

  • ENDEAVOR or Cypher? Comparison of Drug Eluting Stents
  • The ABT578-eluting ENDEAVOR stent has been compared head-to-head with sirolimus-eluting Cypher. Duke University's David Kandzari told us more. [audio:http://www.audiomedica.com/podcasting/aha2005/David_Kandzari.mp3]Click here for

    Post a comment

    Subscribe to Audio Medica Podcast